Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | MC5R | P33032 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10135594 | 0.81 | GPR119 (0.47) | MEN1KMT2ALTA4H | |
| SCHEMBL30824508 | 0.80 | CYP19A1 (0.57) | MEN1KMT2AALDH1A1LTA4HCYP19A1 | |
| SCHEMBL10135802 | 0.80 | PRMT3 (0.43) | PRMT3MEN1KMT2AKDM4ECCR3 | |
| SCHEMBL10135798 | 0.80 | PRMT3 (0.52) | PRMT3MEN1KMT2AP2RX7LTA4H | |
| SCHEMBL10135662 | 0.79 | TBK1 (0.48) | MEN1KMT2ALTA4H | |
| SCHEMBL10135806 | 0.78 | PRMT3 (0.43) | PRMT3MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL10167871 | 0.78 | PRMT3 (0.49) | PRMT3 | |
| SCHEMBL566185 | 0.76 | ATM (0.53) | PRMT3MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL10135592 | 0.76 | GPR119 (0.50) | MEN1KMT2ALTA4H | |
| Hydrochloric Acid SCHEMBL567277 | 0.75 | ATM (0.52) | PRMT3MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | PRMT3 237/4885MEN1 3295/4885KMT2A 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.